The role of central dopamine (DA) receptors in the regulation of blood pressure.
GYKI-32 887 reveals an antihypertensive action, similar to that of the known ergoline derivatives, in conscious SH-rats, in anesthetized normotensive rats, and in cats. It exerts its action first of all by stimulation of the central DA-receptors and by this it reduces the sympathetic activity. The hypotensive effect cannot be detected after icv administration, but both the hypotension and bradycardia can be antagonized by sulpiride administered either icv or iv.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D007276:Injections, Intraventricular; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D013469:Sulpiride / Q000494:pharmacology
D004873:Ergolines; D011954:Receptors, Dopamine; C041696:GYKI 32887; D013469:Sulpiride